請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/43682
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蘇怡寧(Yi-Ning Su) | |
dc.contributor.author | Hsiao-Yin Lu | en |
dc.contributor.author | 盧曉穎 | zh_TW |
dc.date.accessioned | 2021-06-15T02:25:55Z | - |
dc.date.available | 2009-09-15 | |
dc.date.copyright | 2009-09-15 | |
dc.date.issued | 2009 | |
dc.date.submitted | 2009-08-18 | |
dc.identifier.citation | 1. Summers CG: Albinism: classification, clinical characteristics, and recent findings. Optom Vis Sci 2009, 86(6):659-662.
2. Hutton SM, Spritz RA: Comprehensive analysis of oculocutaneous albinism among non-Hispanic caucasians shows that OCA1 is the most prevalent OCA type. J Invest Dermatol 2008, 128(10):2442-2450. 3. Creel D, Garber SR, King RA, Witkop CJ, Jr.: Auditory brainstem anomalies in human albinos. Science 1980, 209(4462):1253-1255. 4. Scriver CR: The metabolic & molecular bases of inherited disease, 8th edn. New York: McGraw-Hill; 2001. 5. Toyofuku K, Wada I, Spritz RA, Hearing VJ: The molecular basis of oculocutaneous albinism type 1 (OCA1): sorting failure and degradation of mutant tyrosinases results in a lack of pigmentation. Biochem J 2001, 355(Pt 2):259-269. 6. King RA, Pietsch J, Fryer JP, Savage S, Brott MJ, Russell-Eggitt I, Summers CG, Oetting WS: Tyrosinase gene mutations in oculocutaneous albinism 1 (OCA1): definition of the phenotype. Hum Genet 2003, 113(6):502-513. 7. King RA, Townsend D, Oetting W, Summers CG, Olds DP, White JG, Spritz RA: Temperature-sensitive tyrosinase associated with peripheral pigmentation in oculocutaneous albinism. J Clin Invest 1991, 87(3):1046-1053. 8. Trevor-Roper PD: Marriage of two complete albinos with normally pigmented offspring. Br J Ophthalmol 1952, 36(2):107-108. 9. Kugelman TP, Van Scott EJ: Tyrosinase activity in melanocytes of human albinos. J Invest Dermatol 1961, 37:73-76. 10. Witkop CJ, Jr., Nance WE, Rawls RF, White JG: Autosomal recessive oculocutaneous albinism in man. Evidence for genetic heterogeneity. Am J Hum Genet 1970, 22(1):55-74. 11. Bakos RM, Argenziano G, Zalaudek I, Masiero NC, Zoratto G, Cartell A, Bakos L: Dermatoscopy of pigmented melanocytic nevi in patients with oculocutaneous albinism. J Am Acad Dermatol 2009, 60(3):487-489. 12. Gronskov K, Ek J, Brondum-Nielsen K: Oculocutaneous albinism. Orphanet J Rare Dis 2007, 2:43. 13. Boissy RE, Zhao H, Oetting WS, Austin LM, Wildenberg SC, Boissy YL, Zhao Y, Sturm RA, Hearing VJ, King RA et al: Mutation in and lack of expression of tyrosinase-related protein-1 (TRP-1) in melanocytes from an individual with brown oculocutaneous albinism: a new subtype of albinism classified as 'OCA3'. Am J Hum Genet 1996, 58(6):1145-1156. 14. Newton JM, Cohen-Barak O, Hagiwara N, Gardner JM, Davisson MT, King RA, Brilliant MH: Mutations in the human orthologue of the mouse underwhite gene (uw) underlie a new form of oculocutaneous albinism, OCA4. Am J Hum Genet 2001, 69(5):981-988. 15. Inagaki K, Suzuki T, Shimizu H, Ishii N, Umezawa Y, Tada J, Kikuchi N, Takata M, Takamori K, Kishibe M et al: Oculocutaneous albinism type 4 is one of the most common types of albinism in Japan. Am J Hum Genet 2004, 74(3):466-471. 16. Mayeur H, Roche O, Vetu C, Jaliffa C, Marchant D, Dollfus H, Bonneau D, Munier FL, Schorderet DF, Levin AV et al: Eight previously unidentified mutations found in the OA1 ocular albinism gene. BMC Med Genet 2006, 7:41. 17. Farabee WC: Notes on Negro Albinism. Science 1903, 17(419):75. 18. Scriver CR: Garrod's Croonian Lectures (1908) and the charter 'Inborn Errors of Metabolism': albinism, alkaptonuria, cystinuria, and pentosuria at age 100 in 2008. J Inherit Metab Dis 2008, 31(5):580-598. 19. Witkop CJ, Jr., White JG, Nance WE, Jackson CE, Desnick S: Classification of albinism in man. Birth Defects Orig Artic Ser 1971, 7(8):13-25. 20. Oetting WS, Fryer JP, Shriram S, King RA: Oculocutaneous albinism type 1: the last 100 years. Pigment Cell Res 2003, 16(3):307-311. 21. Rees JL: Genetics of hair and skin color. Annu Rev Genet 2003, 37:67-90. 22. Yamaguchi Y, Brenner M, Hearing VJ: The regulation of skin pigmentation. J Biol Chem 2007, 282(38):27557-27561. 23. Ito S: The IFPCS presidential lecture: a chemist's view of melanogenesis. Pigment Cell Res 2003, 16(3):230-236. 24. Slominski A, Tobin DJ, Shibahara S, Wortsman J: Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 2004, 84(4):1155-1228. 25. Sturm RA, Teasdale RD, Box NF: Human pigmentation genes: identification, structure and consequences of polymorphic variation. Gene 2001, 277(1-2):49-62. 26. Sturm RA, Box NF, Ramsay M: Human pigmentation genetics: the difference is only skin deep. Bioessays 1998, 20(9):712-721. 27. Tomita Y, Takeda A, Okinaga S, Tagami H, Shibahara S: Human oculocutaneous albinism caused by single base insertion in the tyrosinase gene. Biochem Biophys Res Commun 1989, 164(3):990-996. 28. Giebel LB, Strunk KM, Spritz RA: Organization and nucleotide sequences of the human tyrosinase gene and a truncated tyrosinase-related segment. Genomics 1991, 9(3):435-445. 29. Ray K, Chaki M, Sengupta M: Tyrosinase and ocular diseases: some novel thoughts on the molecular basis of oculocutaneous albinism type 1. Prog Retin Eye Res 2007, 26(4):323-358. 30. Lee ST, Nicholls RD, Jong MT, Fukai K, Spritz RA: Organization and sequence of the human P gene and identification of a new family of transport proteins. Genomics 1995, 26(2):354-363. 31. Ni-Komatsu L, Orlow SJ: Heterologous expression of tyrosinase recapitulates the misprocessing and mistrafficking in oculocutaneous albinism type 2: effects of altering intracellular pH and pink-eyed dilution gene expression. Exp Eye Res 2006, 82(3):519-528. 32. Spritz RA, Fukai K, Holmes SA, Luande J: Frequent intragenic deletion of the P gene in Tanzanian patients with type II oculocutaneous albinism (OCA2). Am J Hum Genet 1995, 56(6):1320-1323. 33. Box NF, Wyeth JR, Mayne CJ, O'Gorman LE, Martin NG, Sturm RA: Complete sequence and polymorphism study of the human TYRP1 gene encoding tyrosinase-related protein 1. Mamm Genome 1998, 9(1):50-53. 34. Jalkanen R, Bech-Hansen NT, Tobias R, Sankila EM, Mantyjarvi M, Forsius H, de la Chapelle A, Alitalo T: A novel CACNA1F gene mutation causes Aland Island eye disease. Invest Ophthalmol Vis Sci 2007, 48(6):2498-2502. 35. Tomita Y: Tyrosinase gene mutations causing oculocutaneous albinisms. J Invest Dermatol 1993, 100(2 Suppl):186S-190S. 36. Summers CG, King RA: Ophthalmic features of minimal pigment oculocutaneous albinism. Ophthalmology 1994, 101(5):906-914. 37. King RA, Wirtschafter JD, Olds DP, Brumbaugh J: Minimal pigment: a new type of oculocutaneous albinism. Clin Genet 1986, 29(1):42-50. 38. Durham-Pierre D, King RA, Naber JM, Laken S, Brilliant MH: Estimation of carrier frequency of a 2.7 kb deletion allele of the P gene associated with OCA2 in African-Americans. Hum Mutat 1996, 7(4):370-373. 39. Hung CC, Chien SC, Lin CY, Chang CH, Chang YF, Jong YJ, Hsieh ST, Hsieh WS, Liu MS, Lin WL et al: Use of multiplex PCR and CE for gene dosage quantification and its biomedical applications for SMN, PMP22, and alpha-globin genes. Electrophoresis 2007, 28(16):2826-2834. 40. Aquaron R, Hesse S, Badens C, Bonerandi JJ: [New nonsense mutation (p.E250X) in the tyrosinase gene of a patient with oculocutaneous albinism type 1A]. Ann Dermatol Venereol 2009, 136(1):57-59. 41. Suzuki T, Miyamura Y, Tomita Y: High frequency of the Ala481Thr mutation of the P gene in the Japanese population. Am J Med Genet A 2003, 118A(4):402-403. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/43682 | - |
dc.description.abstract | 白化症是一種先天性的黑色素生合成異常造成的疾病,由於黑色素的缺乏影響的是全身性的範圍包括全身細胞(皮膚、頭髮以及眼睛),而造成眼睛皮膚型的白化症(OCA),倘若色素缺乏只發生在眼睛部份則會造成眼睛型白化症(OA)。典型的白化症患者終其一生都擁有白皙的皮膚、白色的頭髮以及淡顏色的眼睛虹膜,而且也沒有能曬黑的能力,也因為缺乏黑色素容易造成眼睛部份的特殊病變,其中包括視力衰弱以及眼睛震顫等症狀。臨床上眼睛皮膚型白化症可分為四種類型,四種分型都屬於體染色體隱性遺傳模式,國健局公告的疾病發生率約為 1/15,000- / 1/20,000,至少有四種基因(TYR, OCA2, TYRP1以及MATP基因)被證實會造成白化症。但是由於白化症患者臨床表現型的多樣性造成不同類型的白化症臨床表現多有重覆,因此發展與建立白化症基因分析仍有其必然的重要性,以利於提供後續的遺傳諮詢。
本篇論文中收集了來自於36個家庭中的86個樣本數,其中包含了37位白化症患者,同時利用臨床表現紀錄單收集白化症患者的臨床表現,根據臨床的分型診斷來做基因檢測,利用聚合酶連鎖反應(PCR)、高效能液相層吸法(DHPLC)以及自動化定序儀分析來偵測TYR、P以及MATP基因上的點突變,另外使用Gap PCR 以及 Multiplex PCR來偵測P基因上Exon 7的缺失型突變。 結果顯示有24位白化症患者於TYR基因上發現兩個突變點位,有2位患者於TYR基因上發現一個突變點位。而在P基因方面有7位患者有發現兩個突變點位,而有3位患者只在P基因上發現一個突變點位,此外並沒有在MATP基因上發現任何突變點位。因此,本篇論文中的 37位白化症患者於基因分析中有26 (26/37)位在TYR 基因上發現突變,而10 (10/37)位在P基因上發現突變點位,只有一位患者沒有於TYR、P或MATP基因上發現任何突變點位,將此基因分析的結果與臨床表現型做相關性探討。 由於不同的基因發生突變會造成不同類型的白化症,而白化症目前並無治療的方法,因此利用基因分析的結果不但能幫助家族中患有白化者的家庭成員,給予完善的遺傳諮詢及產前診斷,更能藉此研究來建立台灣族群的白化症基因資料庫,了解台灣人常見的白化症類型以及突變好發點位。 | zh_TW |
dc.description.abstract | The term albinism is applied to define a group of inherited abnormalities of melanin synthesis. The reduction in melanin synthesis can be generalized and involve all melanocytes (including skin, hair follicles, eye etc.), resulting in oculocutaneous albinism (OCA). Classical OCA featured white hair, white skin, and blue eyes, and absence of the ability to tan in the lifelong. In clinical, at least four types of OCA had been categorized. All four types of OCA are inherited as autosomal recessive disorders, and the prevalence rate is between 1/15,000- 1/20,000. At least four genes are responsible for the different types of OCA (TYR, OCA2, TYRP1 and MATP). Due to the overlapping of the clinical manifestations between the OCA subtypes, molecular diagnosis will be helpful in this issue and further genetic counseling.
In this study, 86 individuals including 37 affected individuals diagnosed as OCA clinically and their family members were tested by molecular genetic analysis. Strategy with coupling denaturing high-performance liquid chromatography (DHPLC) and automated sequencing analysis was performed for TYR, P and MATP genes. Both Gap PCR and gene dosage analysis by Multiplex PCR strategies were used to detect the possible rearrangement in P gene. The result revealed 24 patients were identified as a compound heterozygous or homozygous mutation and 2 patients only one mutation was identified in the TYR gene. In the P gene, 7 patients were identified as a compound heterozygous or homozygous mutation and 3 patients only one mutation was identified. No mutation was identified in the MATP gene. However, the total of 37 patients, 26 (26/37) patients had mutation in the TYR gene, 10 (10/37) patients had mutation in the P gene, and only one patient was not identified any pathologic mutation in TYR, P or MATP gene. Due to albinism is an incurable and irreversible disease, the families with increased risk for an affected child may seek for genetic counseling and possible prenatal genetic testing. In this study, we had established a reliable, efficient molecular diagnostic platform and mutation database for patients with OCA in Taiwan. However, further studies are still warrant to elucidate the genotype – phenotype correlation in OCA. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T02:25:55Z (GMT). No. of bitstreams: 1 ntu-98-P96448004-1.pdf: 1293535 bytes, checksum: 4c26bdf9bca822354acddb686a9cc870 (MD5) Previous issue date: 2009 | en |
dc.description.tableofcontents | 總目錄
口試委員會審定書……………………………………………………………………..ii 致謝……………………………………………………………………………………..iii中文摘要……………………………………………………………………………..…iv 英文摘要………………………………………………………………………………. vi 第一章 緒論…………………………………………………………………………...1 1.1 白化症之簡介....................................................................................................1 1.2 疾病分型及臨床表現…………………………………………………………2 1.2.1 眼睛皮膚型白化症第一型(OCA1)…………………………………..2 1.2.1.1 酪胺酸酵素陰性之眼睛皮膚白化症(OCA 1A)………………..3 1.2.1.2 酪胺酸酵素陽性之眼睛皮膚白化症(OCA 1B)………………...3 1.2.2 眼睛皮膚型白化症第二型(OCA2)…………………………………..4 1.2.3 眼睛皮膚型白化症第三型(OCA3)…………………………………..5 1.2.4 眼睛皮膚型白化症第四型(OCA4)…………………………………..6 1.2.5 眼睛型白化症(OA)…………………………………………………...6 1.3 白化症的病理機轉……………………………………………………………7 1.3.1 白化症病因學的演變………………………………………………...7 1.3.2 黑色素的生合成……………………………………………………...7 1.3.3 眼睛皮膚型白化症第一型(OCA1)的病理機轉……………………..8 1.3.4 眼睛皮膚型白化症第三型(OCA3)的病理機轉…………………….9 1.3.5 眼睛皮膚型白化症第二型(OCA2)與第四型(OCA4)的病理機轉...9 1.3.6 眼睛型白化症(OA)的病理機轉……………………………………..9 1.4 白化症之相關基因…………………………………………………………..10 1.4.1 Tyrosinase 基因(TYR gene)…………………………………………10 1.4.2 Pink-Eyed Dilution基因(P or OCA2 gene)………………………….11 1.4.3 Tryosinase-Related Protein 1 基因(TYRP 1 gene)………………….11 1.4.4 Membrane-Associated Transporter Protein基因(MATP gene)……...11 1.4.5 Ocular Albinism 基因(OA gene)……………………………………12 1.5 白化症之診斷方法與臨床運用……………………………………………..12 1.5.1 聚合酶連鎖反應(PCR)之原理……………………………………..12 1.5.2 Gap PCR之原理應用……………………………………………….12 1.5.3 Multiplex PCR與毛細管電泳(CE)之原理.………………………....13 1.5.4 高效能液相層析儀(DHPLC)之原理………………………………14 1.6 研究動機…………………………………………………………………….14 第二章 實驗材料與儀器……………………………………………………………16 2.1實驗材料與試劑……………………………………………………………..16 2.1.1 人類基因體DNA…………………………………………………....16 2.1.2 引子對(Primer)………………………………………………………16 2.1.3 聚合酶連鎖反應試劑………………………………………………16 2.1.4 洋菜凝膠電泳所需的試劑………………………………………….16 2.1.5 DHPLC試劑組………………………………………………………17 2.1.6 自動化DNA定序試劑組……………………………………………17 2.2 實驗儀器……………………………………………………………………..17 2.2.1 磁珠分離式核酸萃取系統………………………………………….17 2.2.2 PCR熱循環器……………………………………………………….17 2.2.3 水平式電泳槽……………………………………………………….17 2.2.4 DHPLC分析儀………………………………………………………17 2.2.5 High-Performance DNA analysis system (HDA)……………………17 2.2.6 DNA序列分析儀……………………………………………………17 第三章 實驗方法……………………………………………………………………18 3.1萃取DNA……………………………………………………………………18 3.2聚合酶連鎖反應(Polymerase Chain Reaction, PCR)………………………..18 3.3洋菜凝膠電泳(Agarose gel electrophoresis)…………………………………18 3.4 Gap PCR……………………………………………………………………..19 3.5 Multiplex PCR 與毛細管電泳(CE)………………………………………….19 3.6自動化定序分析(Automated DNA Sequencing)與結果確認………………..20 3.7 DNA片段突變分析儀(DHPLC)……………………………………………..20 第四章 實驗結果…………………………………………………………………….22 4.1白化症患者臨床表現資料收集……………………………………………..22 4.2 Tyrosinase基因(TYR gene)之分析結果…………………………………….23 4.2.1 Point Mutation以聚合酶連鎖反應後定序之基因分析結果…………23 4.3 Pink-Eyed Dilution基因( P gene)之分析結果……………….….................24 4.3.1 Point Mutation以聚合酶連鎖反應後定序之基因分析結果…………24 4.3.2運用Gap PCR 檢測Deletion Type之結果………………………….25 4.3.3運用Multiplex PCR 與毛細管電泳檢測Deletion Type之結果…….25 4.4 MATP基因之分析結果……………………………………………………..25 4.5基因分析結果之總整…………………………………………………………26 第五章 討論…………………………………………………………………………27 5.1 臨床表現型收集探討……………………………………………………….27 5.2 基因分析結果之探討……………………………………………………….27 5.2.1 Point mutation之分析結果……………………………………………27 5.2.2 Cryptic mutation之探討………………………………………………28 5.3白化症基因型與表現型相關性之探討……………………………………..29 5.4 遺傳諮詢之運用……………………………………………………………31 第六章 結語………………………………………………………………………..33 第七章 參考資料……………………………………………………………………34 圖目錄 圖一 黑色素生成生化途徑…………………………………………………………38 圖二 造成白化症的基因於黑色素生合成過程中所在位置……………………….39 圖三 Gap PCR 引子位置圖…………………………………………………………40 圖四 本論文實驗流程圖…………………………………………………………….41 圖五 TYR 基因突變點位圖…………………………………………………………42 圖六 DHPLC與定序之結果圖……………………………………………………..43 圖七 P 基因基因突變點位圖……………………………………………………..44 圖八 Gap PCR於P基因Exon 7 2.7kb缺失型及無缺失型跑膠之預期結果…….45 圖九 Gap PCR於P基因Exon 7 無2.7kb缺失型(240bp片段)之跑膠結果……..46 圖十 Multiplex PCR與毛細管電泳之結果圖………………………………………47 圖十一 白化症患者基因分型檢測率………………………………………………..48 圖十二 白化症患者各基因之檢測率………………………………………………...49 表目錄 表一 各類型白化症之臨床表現…………………………………………………… 50 表二 Genes Associated with Non-syndromic OCA………………………………….51 表三 聚合酶連鎖反應所使用之TYR 基因引子對…………………………………52 表四 聚合酶連鎖反應所使用之P 基因引子對……………………………………53 表五 聚合酶連鎖反應所使用之MATP 基因引子對………………………………55 表六 聚合酶連鎖反應所使用之所需理想反應試劑條件………………………….56 表七 聚合酶連鎖反應之理想反應條件參數……………………………………….57 表八 Gap PCR所使用之P 基因引子對……………………………………………58 表九 Gap PCR所使用之所需理想反應試劑條件…………………………………..59 表十 Multiplex PCR所使用之引子對……………………………………..………..60 表十一 Multiplex PCR之所需理想反應試劑條件…………………………………. 61 表十二 Clinical Criteria for Oculocutaneous Albinism Sheet………………………..62 表十三 臨床表現型收集之結果……………………………………………………...64 表十四 白化症患者臨床表現初步分類及其基因型………………………………...69 表十五 眼睛虹膜顏色為紅色之白化症患者………………………………………72 表十六 眼睛虹膜顏色為藍色之白化症患者………………………………………...73 表十七 TYR 基因的突變點位………………………………………………………..74 表十八 TYR 基因單一核苷酸多型性點位(SNP)……………………………………75 表十九 P 基因突變點位……………………………………………………………..76 表二十 P基因單一核苷酸多型性點位(SNP)……………………………………….77 表二十一 MATP基因單一核苷酸多型性點位(SNP)……………………………….78 表二十二 OCA 1患者於TYR 基因上發現的突變點位之各發生頻率……………..79 表二十三 OCA 2患者於P 基因上發現的突變點位之各發生頻率………………..80 表二十四 臨床診斷與基因分析不一致之個案…………………………………….. 81 表二十五 Only one pathological mutation can be identified………………………….82 表二十六 沒有出現眼睛震顫的患者………………………………………………..83 | |
dc.language.iso | zh-TW | |
dc.title | 台灣眼睛皮膚型白化症患者之基因分析
與基因型-表現型之研究:基因檢測之重要性 | zh_TW |
dc.title | Genetic analysis and genotype-phenotype studies in Taiwanese patients with oculocutaneous albinism:
the importance of molecular genetic testing | en |
dc.type | Thesis | |
dc.date.schoolyear | 97-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林炫沛(Shuan-Pei Lin),楊偉勛(Wei-Shiung Yang) | |
dc.subject.keyword | 眼睛皮膚型白化症(OCA),TYR基因,P基因,MATP 基因,基因診斷,基因檢測,遺傳諮詢, | zh_TW |
dc.subject.keyword | Oculocutaneous albinism (OCA),TYR gene,P gene,MATP gene,Molecular diagnosis,Molecular genetic testing,Genetic counseling, | en |
dc.relation.page | 83 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2009-08-18 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
顯示於系所單位: | 分子醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-98-1.pdf 目前未授權公開取用 | 1.26 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。